Market researchers predict the global facial injectable market which was $7,125.65 million in 2017 will balloon to more than $18,819.04 million by 2026, according to a report published June 2018 by Polaris Market Research.
Facial injectables include hyaluronic acid, collagen dermal fillers, as well as synthetic fillers, including calcium hydroxylapatite and polymethyl methacrylate microspheres. The facial injectable market also includes botulinum toxin A and poly-L-lactic acid (PLLA) micro particle injectables.
While the market for facial injectables is primarily women ages 35 to 60 years, men and both genders’ desires for nonsurgical options in facial rejuvenation also factor into the growing demand, according to the Polaris report [https://www.polarismarketresearch.com/industry-analysis/global-facial-injectable-market/#utm_source=whatech&utm_content=whatech.com/510600].
A report by Millennium Research Group focusing on the U.S. facial injectable market suggests the domestic market will be above $2 billion by 2025. Emerging groups including men and younger patients will fuel the rising demand, according to Millennium Research. https://www.giiresearch.com/report/mrg292252-us-markets-facial-injectables.html
Common indications for injectable fillers in men are periorbital, according to facial plastic surgeon Patrick J. Byrne, M.D., M.B.A., director of facial plastic and reconstructive surgery at Johns Hopkins University School of Medicine and an American Academy of Facial Plastic and Reconstructive Surgery board member.
“In this scenario, we treat the eyelid cheek junction with filler to reduce the signs of aging and fatigue. We like hyaluronic acid, including Belotero [Merz] and Restylane [Galderma], for the indication,” Dr. Byrne says.
Other reports corroborate on the market’s growth potential, including one published in May 2017 by Grand View Research. It puts the value of the 2016 global facial injectables market at $6.5 billion and predicts the market will grow at a compound annual growth rate of 11.5% through 2025.
Increasing consumer awareness about their aesthetic options and a growing geriatric population will drive market growth, according to Grand View Research’s report https://www.grandviewresearch.com/industry-analysis/facial-injectables-industry, published November 2016.
Grand View predicts not only aesthetic uses but also therapeutic applications of botulinum toxin type A products will bolster demand for those products.
Yet another report on the global dermal fillers market published Dec. 5, 2017, by Future Market Insights https://www.futuremarketinsights.com/reports/dermal-fillers-market, predicts that reconstructive applications of dermal fillers will greatly boost the market through 2027. Those applications include treatments for acne scaring and HIV-induced facial lipoatrophy.
“We see a growing demand for the use of injectable treatments for not only acne scarring but also post-traumatic scars,” Dr. Byrne says.
Medical conditions which result in soft tissue volume loss in the face include not only HIV induced lipoatrophy but also congenital conditions, such as Parry-Romberg syndrome, according to Dr. Byrne.
“There is also a need for effective solutions for many of our wounded warriors who returned from combat overseas with extremity injuries, many of which have significant soft tissue volume deficits,” Dr. Byrne says. “Here at Johns Hopkins, we are now in the midst of a phase 2 FDA clinical trial of a novel bio-filler material. It is crafted from acellular human adipose tissue, and has fascinating regenerative properties. We believe this has the potential to add an important new option in the armamentarium of reconstructive surgeons.”
Dr. Byrne agrees that consumer demand for dermal fillers and neuromodulators will continue to climb.
“I think the materials are improving, there are greater number of filler options with each passing year and, also importantly, we as providers are becoming more sophisticated and nuanced in their application,” he says.